References
- Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
- Townsend J. Urogenital atrophy in the post-menopausal woman. Continence UK 2007;1:15–19
- Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
- Smith RN, Studd JW. Recent advances in hormone replacement therapy. Br J Hosp Med 1993;49:799–808
- Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–8
- Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661–6
- Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292–303
- Smith AL, Wein AJ. Estrogen replacement therapy for the treatment of postmenopausal genitourinary tract dysfunction. Discov Med 2010;10:500–10
- Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42
- Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722–7
- Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63: 138–41
- Graziottin A, Leiblum SR. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J Sex Med 2005;2(Suppl 3):133–45
- Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009;6:603–16; quiz 18–19
- Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67:233–8
- Nappi RE, Liekens G, Brandenburg U. Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey. Contraception 2006;73:493–500
- Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008;51:549–55
- MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
- Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. Clin PharmacolTher 2011;89: 129–32
- Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112: 1053–60
- Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets. Climacteric 2010;13:219–27
- Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;13: 228–37